GlassScriptPhysician profile
Augustus T Stephens
NPI 1669554598
$5,473.64
in general payments reported to CMS, 2019-2025
29 companies · $661 in 2025
The $661 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $929 · 2021: $886 · 2022: $755 · 2023: $351 · 2024: $1,109 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $863.72 | 2019-2022 | |
| Alcon Vision LLC | $834.29 | 2019-2025 | Rocklatan, Ngenuity, Clareon |
| Coopervision INC. | $500.00 | 2021-2022 | |
| Abbvie INC. | $469.55 | 2022-2025 | Lumigan, Alphagan P |
| Johnson & Johnson Surgical Vision, INC. | $453.85 | 2019-2024 | Tecnis Iol, Tecnis Simplicity, Catalys System |
| Novartis Pharmaceuticals Corporation | $281.59 | 2019-2023 | |
| New World Medical,INC. | $227.07 | 2022-2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Glaukos Corporation | $207.19 | 2019-2025 | Idosetr, Radius |
| Eyevance Pharmaceuticals LLC | $194.71 | 2020-2021 | |
| Rxsight INC | $163.36 | 2022-2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Sun Pharmaceutical Industries INC. | $161.04 | 2019-2022 | |
| Shire North American Group INC | $160.39 | 2019 | |
| Bausch & Lomb Americas INC. | $149.04 | 2022-2025 | Xiidra, Miebo |
| Sight Sciences, INC. | $123.90 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Dompe US, INC. | $95.26 | 2022-2025 | Oxervate |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $87.64 | 2025 | Vevye |
| Thea Pharma INC. | $87.34 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $69.47 | 2019-2021 | |
| Genentech USA, INC. | $67.46 | 2024-2025 | Vabysmo |
| Amgen INC. | $44.37 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $38.02 | 2019-2025 | |
| Akorn Operating Company LLC | $37.47 | 2021 | |
| Mallinckrodt Hospital Products INC. | $27.76 | 2022 | |
| Aerie Pharmaceuticals, INC. | $27.53 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $22.21 | 2025 | Xdemvy |
| Astellas Pharma US INC | $22.05 | 2025 | Izervay |
| Ivantis, INC | $21.05 | 2021 | |
| Eyepoint US, INC. | $20.38 | 2020 | |
| Oyster Point Pharma, INC. | $15.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustus Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.